Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Tg Therapeutics (TGTX) over the last 5 years, with Dec 2024 value amounting to $0.15.

  • Tg Therapeutics' EPS (Weighted Average and Diluted) rose 12050.00% to $2.43 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.78, marking a year-over-year increase of 2627.27%. This contributed to the annual value of $0.15 for FY2024, which is 66.67% up from last year.
  • Tg Therapeutics' EPS (Weighted Average and Diluted) amounted to $0.15 in FY2024, which was up 66.67% from $0.09 recorded in FY2023.
  • Over the past 5 years, Tg Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.15 during FY2024, and registered a low of -$2.63 during FY2021.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was $0.09 (2023), whereas its average is -$0.47.
  • As far as peak fluctuations go, Tg Therapeutics' EPS (Weighted Average and Diluted) fell by 8.36% in 2021, and later spiked by 105.45% in 2023.
  • Yearly analysis of 5 years shows Tg Therapeutics' EPS (Weighted Average and Diluted) stood at -$2.43 in 2020, then dropped by 8.36% to -$2.63 in 2021, then surged by 37.26% to -$1.65 in 2022, then surged by 105.45% to $0.09 in 2023, then skyrocketed by 66.67% to $0.15 in 2024.